Chemotherapeutic agents and the skin: An update

作者: Noushin Heidary , Haley Naik , Susan Burgin

DOI: 10.1016/J.JAAD.2008.01.001

关键词:

摘要: Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous of longstanding have been extensively studied and reviewed. Over last 2 decades, a number new molecular entities for treatment cancer approved by United States Food Drug Administration (FDA). This article reviews cutaneous toxicity patterns these agents. It also one drug has not received FDA approval but is in use outside important dermatologically. Particular emphasis placed on novel signal transduction inhibitors as newer literature pertaining previously reactions. Learning objectives At completion this learning activity, participants should able list chemotherapeutic possess significant side describe range reactions are seen with each drug. In addition, they be formulate appropriate management strategies

参考文章(297)
John J. Kavanagh, Irwin H. Krakoff, Gerald P. Bodey, Phase I study of fludarabine (2-Fluoro-ara-AMP) European Journal of Cancer and Clinical Oncology. ,vol. 21, pp. 1009- 1011 ,(1985) , 10.1016/0277-5379(85)90283-4
Davin S. Lim, James Muir, Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology. ,vol. 205, pp. 169- 171 ,(2002) , 10.1159/000063899
K Prabhash, Ghanshyam Biswas, N Prasad, Narayan Karant, PSRK Sastry, PM Parikh, Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian Journal of Dermatology, Venereology and Leprology. ,vol. 72, pp. 63- 64 ,(2006) , 10.4103/0378-6323.19727
T. YANAGI, D. SAWAMURA, H. SHIMIZU, Follicular mucinosis associated with imatinib (STI571). British Journal of Dermatology. ,vol. 151, pp. 1276- 1278 ,(2004) , 10.1111/J.1365-2133.2004.06295.X
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Jim Cassidy, Jean-Louis Misset, Oxaliplatin-related side effects: characteristics and management. Seminars in Oncology. ,vol. 29, pp. 11- 20 ,(2002) , 10.1053/SONC.2002.35524
Mi-Woo Lee, Chul-Won Seo, Sang-We Kim, Hwa-Jeong Yang, Hae-Woong Lee, Jee-Ho Choi, Kee-Chan Moon, Jai-Kyoung Koh, Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Dermato-venereologica. ,vol. 84, pp. 23- 26 ,(2003) , 10.1080/00015550310005898
J. Dalmau, L. Peramiquel, L. Puig, M.T. Fernández-Figueras, E. Roé, A. Alomar, Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. British Journal of Dermatology. ,vol. 154, pp. 1213- 1216 ,(2006) , 10.1111/J.1365-2133.2006.07276.X
G Blackledge, S Averbuch, Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. British Journal of Cancer. ,vol. 90, pp. 566- 572 ,(2004) , 10.1038/SJ.BJC.6601550